Evidence map›Paper›PMID 30791458›Full record

ArticleCancers2019

Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches.

Janette Beshay, Peter Jantscheff, Thomas Lemarchand, Cynthia Obodozie, Christoph Schächtele, Holger Weber

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Mouse Tumor Models for Advanced Cancer Immunotherapy.International journal of molecular sciences · 2020
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Janette BeshayIn Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, Germany. Janette_Beshay@web.de.
Peter JantscheffIn Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, Germany. peter.jantscheff@t-online.de.
Thomas LemarchandTPL Pathology Labs, Sasbacher Str. 10, 79111 Freiburg, Germany. lemarchand@tpl-path-labs.com.
Cynthia ObodozieIn Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, Germany. c.obodozie@proqinase.com.
Christoph SchächteleIn Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, Germany. c.schaechtele@proqinase.com.
Holger WeberIn Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, Germany. h.weber@proqinase.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this second study, we established syngeneic in vivo models named carcinogen-induced mouse-derived isografts (cMDIs). Carcinogen-induced tumors were obtained during short-term observation (3⁻9 months) of CBA/J mice treated with various administration routes with 3-methylcholanthrene (MCA) or

Indexed as

carcinogen-induced tumorsexperimental cancerimmune checkpoint inhibitorsimmunocompetent animalsmouse-derived isografts (MDIs)mouse tumor modelssyngeneictherapy

Identifiers

PMID30791458
PMCPMC6406786
OpenAlexW2911712776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.